OctariusRx, LLC的动态

Vantive's mission, "Extending Lives, Expanding Possibilities," underscores its commitment to advancing vital organ therapies for acute and chronic kidney diseases. This mission drives employees to develop innovative solutions that meet the unique needs of clinicians and patients, enhancing the healthcare experience. Baxter announces branding for its spin-off kidney care business with the plum-coloured "V" logo, divided into three parts, representing Vantive's focus on innovative therapies, digital solutions, and advanced services, combining the stability of Baxter’s blue with the boldness of red. ? Building on Baxter's nearly 70-year legacy in kidney care, Vantive will serve over one million patients annually in more than 70 countries. Chris Toth, transitioning from executive vice president at Baxter to Vantive's CEO, will lead the new company. Vantive plans to launch through a sale or spinoff in the second half of 2024, following Baxter's 2023 announcement. Until then, the kidney care business will continue under Baxter's name. ? https://lnkd.in/gaaXUhrS. #MedTechNews #MedicalDevices #HealthcareInnovation #MedTechIndustry #HealthTech #HealthcareTechnology #MedDeviceNews #HealthcareNews #MedTechTrends

Sonic Healthcare (ASX: SHL) is expanding its interests in the European market with the acquisition of LADR, a major medical testing operation in Germany that has been family owned and led for almost 80 years, in a deal worth €423 million ($698.5 million). LADR, an acronym for Laboratory Group Dr. Kramer & Colleagues, is one of the top ...https://lnkd.in/gfMrb2gr

Following my previous "Field of Dreams" post, it's time for another edition of Movie Quote Monday (ok, I just made that up) to review how classic movies help shine a light on wasteful Rx spending and the important work we're doing at Walrus Health. In 1980's "Caddyshack," Ty Webb (Chevy Chase) famously asks his caddy, "Do you take drugs, Danny?" "Everyday," he responds. "Good. So what's the problem?" Although they probably weren't referring to Rx meds, the idea that "as long as people are adherent, everything is fine" is a common misconception. However, a study published in 2022 showed that non-adherence was just the sixth most common medication issue, with things like dose too high/too low, missing meds, ineffective meds, and adverse drug reactions all ranking higher in frequency than non-adherence. So what does this mean for benefits leaders looking to rein in out-of-control Rx spending? It's critical to look beyond your claims data and plan-level controls to actively manage medications at the individual level. At Walrus, we're connecting our clients' most costly and complex plan members directly with clinical pharmacists to find our what's working, what's not, and what more cost-effective paths exist. Those continuous member insights are critical to identifying and eliminating wasteful Rx spending on meds that aren't needed, aren't working, or are causing harmful side effects. After all, just because someone *can* be on a drug doesn't mean they *should* be. P.S. Be the ball.

Reflecting on an Incredible 2024: Zymego’s Year of Success 2024 has been an extraordinary year for Zymego, filled with remarkable achievements and milestones. How did we reach such heights? Let’s take a look at some key numbers and moments that defined our success: * Over 100,000 patients have used Zymego to shorten their waiting times. * 968 years of patient waiting times reduced. * Accredited to sell to the NHS. * Achieved ISO 27001 certification. * I was accredited as the Clinical Safety Officer for Zymego in the UK. What makes us so successful? First and foremost, it’s the clinics using Zymego—the rebels and trailblazers of healthcare who see the value of automation and work tirelessly to reduce patient waiting times. Without all the forward-thinking people working at these clinics, Zymego wouldn’t be where it is today. Additionally, our incredible team has relentlessly strived to improve and expand Zymego’s reach, making it available to even more patients. Where to now? Upwards and onwards! The growth rate is dizzying, but one of many amazing stories stuck with me, hearing that one clinic using Zymego has helped clinics reduce the number of monthly voicemails left by patients from 3,000 to 400. That’s a real impact! My most memorable moment: A patient shared that thanks to a late-cancelled appointment via Zymego, their clinic detected cancer in time. This is why we do what we do. A huge thank you to all the clinics striving towards our shared goal of zero wasted appointments, and to Team Zymego—we’ve achieved incredible things in 2024. Let’s make 2025 even better!

Day 5 of #SciComm -- Susceptibility test breakpoints are complex, complicated, hard to keep with or understand, but VERY important to patient care and safety. ?? American Society for Microbiology American Society for Clinical Laboratory Science

As the nationwide IV fluid shortage continues, the effects are reaching beyond critical care. Non-emergency surgeries—procedures that are essential for quality of life but not immediately life-threatening—are facing delays across the country. With a reduced supply of essential IV fluids, healthcare providers are forced to prioritize emergency cases, leaving many patients waiting longer for scheduled procedures. This situation underscores the urgent need for resilient supply chains in healthcare. Patients awaiting surgeries like joint replacements, hernia repairs, or routine biopsies are experiencing extended wait times, increased anxiety, and potential health complications from delayed care. At Nextgen Pharmaceuticals, we believe in the power of proactive supply chain management to support uninterrupted patient care. We’re committed to helping healthcare providers maintain access to critical IV solutions during these challenging times, so patients receive the care they need, when they need it.

BAM! If you've followed me for a while on Illumina/GRAIL you'll know that I've long been skeptical of the NHS acceptance of GRAIL - clinicians there have been pushing back hard in public against what was probably a politically-driven Illumina/David Cameron partnership. Last week the GRAIL management team doubled down on their dependence on the NHS by mentioning it FIFTY times in their two hour call. It is the anchor of their reimbursement strategy NHS->FDA->CMS. Well, today's there's NHS news and it's bad: the NHS is NOT moving forward with a Galleri pilot. Check out the last paragraph, it's a brutal analysis of GRAIL's future prospects, written by GRAIL itself. From the Form 10 (via Jack Meehan, CFA.): "The NHS determined not to initiate the pilot on the basis of [available] data and will evaluate the final results from the NHS-Galleri Trial, which are expected to be available in 2026, before determining whether to implement the Galleri test in the NHS." "While the NHS intended to commence the commercial pilot if it determined that the results of the early analysis were compelling, it is possible that the final results will be unsuitable to the NHS, which could have a significant adverse impact on the success of our commercial efforts for Galleri, our ability to achieve FDA authorization AT ALL or within our anticipated timelines, our BRAND and REPUTATION, our BUSINESS, and our GROWTH PROSPECTS” [Timing couldn't be worse with the spinout pending this month. Kind of feels like the end to me, I don't see where they go now ??]

We have some exciting news to share this morning: results from our Epic Willow Inpatient workflow integration with Ballad Health have been circulated via the below press release. Spoiler alert: there's been a consistent 70% alert actionability performance rating by Ballad Health #Pharmacists! Key outtakes from Ballad Health Chief Pharmacy Officer, Trish Tanner and MedAware CEO, David Franklin: "We are proud to be at the forefront of innovation in medication safety by deploying MedAware's AI-driven solutions. This technology has the potential to make a profound impact on patient safety and outcomes while also driving real efficiencies in the way pharmacy delivers care. By leveraging MedAware's platform, we are taking a proactive approach towards delivering all our patients the highest standard of care." (Trish Tanner) "We are grateful for the work of Ballad Health in supporting MedAware's integration. Health systems are most apt to take advantage of innovation when they leverage their existing toolset, realizing incremental value from prior tech investments. We are excited about the power of clinician-enabled AI to pair alongside healthcare pharmacy teams, empowering them to do more and more safely." (David Franklin) #ClinicalAI #MedicationSafety #PatientSafety #Pharmacy #PharmacyInnovation #EHRworkflow #AlertBurden #AlertReduction #Efficiency #PharmacyOperations https://lnkd.in/ezefUMdp

How can an entity-owned Specialty Pharmacy increase medication access for underserved populations, improving patient care and providing opportunities for efficiency and enhancement across hospital operations? Read more in this latest interview with Carmine DeNardo, vice president and general manager of Omnicell's Specialty Pharmacy Services. https://okt.to/QCELtz

Pickard et al do a good job of talking through one of the biggest self-inflicted challenges we have in healthcare...competing for wRVUs. It's hard to play like you are on the same team, when the compensation model shows that you aren't. Comp models need to embrace not just what is permissible but what advances the patient experience and practice success. #marketaccess https://lnkd.in/gaWGaUhV